Is RGC or SHPH more undervalued in 2026?

CirclFi compares Regencell Bioscience Holdings L (RGC) and Shuttle Pharmaceuticals Holding (SHPH) using 13 institutional-grade valuation models. RGC has a Quality of Company score of 4.6/10 while SHPH scores 3.6/10.

Which is a better buy — RGC or SHPH?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do RGC and SHPH valuations compare?

RGC at $24.11 and SHPH at $0.54 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

RGC vs SHPH Valuation Comparison 2026 — Intrinsic Value Analysis

RGC

Drug Manufacturers - Specialty & Generic

Regencell Bioscience Holdings L

Quality

4.6

out of 10

Value Trap

SAFE

Price

$24.11

Last close

Models

10/13

Active

SHPH

Drug Manufacturers - Specialty & Generic

Shuttle Pharmaceuticals Holding

Quality

3.6

out of 10

Value Trap

SAFE

Price

$0.54

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	RGC Fair Value	RGC Upside	SHPH Fair Value	SHPH Upside
Bayesian DCF	Intrinsic	$8.05	-66.6%	$3.22	+464.6%
Earnings Power Value	Intrinsic	$11.09	-59.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$0.01	-100.0%	$0.08	-88.0%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for RGC vs SHPH — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

RGC vs SHPH — Which Stock Is More Undervalued?

RGC scores higher with a 4.6/10 quality rating vs SHPH's 3.6/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Regencell Bioscience Holdings L (RGC) and Shuttle Pharmaceuticals Holding (SHPH) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

RGC currently trades at $24.11 with a QOC of 4.6/10, while SHPH trades at $0.54 with a QOC of 3.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).